Product Description
Menadione is a member of the class of 1,4-naphthoquinones that is 1,4-naphthoquinone which is substituted at position 2 by a methyl group. It is used as a nutritional supplement and for the treatment of hypoprothrombinemia. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Menadione)
Mechanisms of Action: Coagulation Cofactor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Chile | Dominican Republic | India | Malta | Mexico | New Zealand | Pakistan | Philippines | Russia | Taiwan | Turkey | Ukraine | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Folliculitis
Phase 1: Exanthema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MC10C9 | N/A |
Active, not recruiting |
Skin Cancer |
2013-05-11 |
|
| Vitamin K3 | P2 |
Terminated |
Folliculitis |
2012-07-31 |
|
| HBS701 | P1 |
Completed |
Exanthema |
2009-12-30 |
45% |